close 76% of retail accounts lose money when trading CFDs with this provider. Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
SearchSearch
Change languageEnglish (International)
Dashboard

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Home・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

4.31 -2.71

Strong Buy

Price update 26 Jun 2025, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

4.23

Max

4.47

Key metrics

By Trading Economics

Income

7.3M

-23M

Sales

-527K

30M

EPS

-2.77

Profit margin

-78.168

Employees

279

EBITDA

-14M

-33M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+417.82% upside

Market Stats

By TradingEconomics

Market Cap

-15M

37M

Previous open

7.02

Previous close

4.31

News Sentiment

By Acuity

50%

50%

154 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Jun 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

DJ

Read

26 Jun 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

DJ

Read

26 Jun 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

DJ

Read

26 Jun 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

DJ

Read

26 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

DJ

Read

26 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

DJ

Read

26 Jun 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

DJ

Read

26 Jun 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

DJ

Read

26 Jun 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

DJ

Read

26 Jun 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

DJ

Read

26 Jun 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

DJ

Read

26 Jun 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

DJ

Read

26 Jun 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

DJ

Read

26 Jun 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

DJ

Read

26 Jun 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

DJ

Read

26 Jun 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Read

26 Jun 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

DJ

Read

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

DJ

Read

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

DJ

Read

26 Jun 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

DJ

Read

26 Jun 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Read

26 Jun 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

DJ

Read

26 Jun 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

DJ

Read

26 Jun 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

DJ

Read

26 Jun 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Read

26 Jun 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Read

26 Jun 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

DJ

Read

26 Jun 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

DJ

Read

26 Jun 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

26 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

417.82% upside

12 Months Forecast

Average 23.25 USD  417.82%

High 42 USD

Low 8 USD

Based on 4 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Based on 4 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

154 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

795.48

↑ +0.43%

JNJ

Johnson and Johnson

152.14

↓-0.14%

ABBV

AbbVie Inc

186.94

↑ +0.72%

NVO

Novo Nordisk A-S

67.74

↑ +0.61%

UNH

UnitedHealth Group Inc

302.46

↑ +0.12%